CLL Sector Heats Up, AbbVie/Roche Upbeat About First-Line Venetoclax Combo

 
• By John Davis

Positive top-line data on use of an AbbVie/Genentech's venetoclax combination as a first-line chronic lymphocytic leukemia therapy heralds stiffer competition in the therapeutic sector in the years to come.  

Cycling
CLL market is likely to see increased competition • Source: Shutterstock.

More from Anticancer

More from Therapy Areas